PDB-4qml: MST3 in complex with AMP-PNP 手法: X-RAY DIFFRACTION / 解像度: 1.882 Å
PDB-4qmm: MST3 IN COMPLEX WITH AT-9283, 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]-1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM 手法: X-RAY DIFFRACTION / 解像度: 1.852 Å
PDB-4qmn: MST3 in complex with BOSUTINIB 手法: X-RAY DIFFRACTION / 解像度: 2.091 Å
PDB-4qmo: MST3 IN COMPLEX WITH Imidazolo-oxindole PKR inhibitor C16 手法: X-RAY DIFFRACTION / 解像度: 1.898 Å
PDB-4qmp: MST3 IN COMPLEX WITH CDK1/2 INHIBITOR III, 5-AMINO-3-{[4-(AMINOSULFONYL)PHENYL]AMINO}-N-(2,6-DIFLUOROPHENYL)-1H-1,2,4-TRIAZOLE-1-CARBOTHIOAMIDE 手法: X-RAY DIFFRACTION / 解像度: 2 Å
PDB-4qmq: MST3 in complex with CP-673451 手法: X-RAY DIFFRACTION / 解像度: 1.769 Å
PDB-4qms: MST3 in complex with DASATINIB 手法: X-RAY DIFFRACTION / 解像度: 1.883 Å
PDB-4qmt: MST3 in complex with HESPERADIN 手法: X-RAY DIFFRACTION / 解像度: 1.5 Å
PDB-4qmu: MST3 IN COMPLEX WITH JNJ-7706621, 4-({5-AMINO-1-[(2,6-DIFLUOROPHENYL)CARBONYL]-1H-1,2,4-TRIAZOL-3-YL}AMINO)BENZENESULFONAMIDE 手法: X-RAY DIFFRACTION / 解像度: 1.546 Å
PDB-4qmv: MST3 IN COMPLEX WITH PF-03814735, N-{2-[(1S,4R)-6-{[4-(CYCLOBUTYLAMINO)-5-(TRIFLUOROMETHYL)PYRIMIDIN-2-YL]AMINO}-1,2,3,4-TETRAHYDRO-1,4-EPIMINONAPHTHALEN-9-YL]-2-OXOETHYL}ACETAMIDE 手法: X-RAY DIFFRACTION / 解像度: 2.4 Å
PDB-4qmw: MST3 IN COMPLEX WITH PP-121, 1-CYCLOPENTYL-3-(1H-PYRROLO[2,3-B]PYRIDIN-5-YL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE 手法: X-RAY DIFFRACTION / 解像度: 1.6 Å
PDB-4qmx: MST3 in complex with SARACATINIB 手法: X-RAY DIFFRACTION / 解像度: 1.882 Å
PDB-4qmy: MST3 IN COMPLEX WITH STAUROSPORINE 手法: X-RAY DIFFRACTION / 解像度: 1.883 Å
PDB-4qmz: MST3 IN COMPLEX WITH SUNITINIB 手法: X-RAY DIFFRACTION / 解像度: 1.88 Å
PDB-4qna: MST3 IN COMPLEX WITH 2-(4,6-Diamino-1,3,5-triazin-2-yl)phenol 手法: X-RAY DIFFRACTION / 解像度: 1.849 Å
PDB-4qo9: MST3 IN COMPLEX WITH Danusertib 手法: X-RAY DIFFRACTION / 解像度: 2.2 Å